Multiple functions of G protein-coupled receptor kinases

Journal of Molecular Signaling

Hitoshi Kurose¹  Michio Nakaya¹  Kenji Watari¹ 

[1] Department of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

关键词: Biased agonist;    Cell signaling;    G protein-coupled receptor kinase (GRK);    G protein-coupled receptor (GPCR);   

Others  :  802290
DOI  :  10.1186/1750-2187-9-1

 received in 2013-12-27, accepted in 2014-02-25,  发布年份 2014

【 摘 要 】

Desensitization is a physiological feedback mechanism that blocks detrimental effects of persistent stimulation. G protein-coupled receptor kinase 2 (GRK2) was originally identified as the kinase that mediates G protein-coupled receptor (GPCR) desensitization. Subsequent studies revealed that GRK is a family composed of seven isoforms (GRK1–GRK7). Each GRK shows a differential expression pattern. GRK1, GRK4, and GRK7 are expressed in limited tissues. In contrast, GRK2, GRK3, GRK5, and GRK6 are ubiquitously expressed throughout the body. The roles of GRKs in GPCR desensitization are well established. When GPCRs are activated by their agonists, GRKs phosphorylate serine/threonine residues in the intracellular loops and the carboxyl-termini of GPCRs. Phosphorylation promotes translocation of β-arrestins to the receptors and inhibits further G protein activation by interrupting receptor-G protein coupling. The binding of β-arrestins to the receptors also helps to promote receptor internalization by clathrin-coated pits. Thus, the GRK-catalyzed phosphorylation and subsequent binding of β-arrestin to GPCRs are believed to be the common mechanism of GPCR desensitization and internalization. Recent studies have revealed that GRKs are also involved in the β-arrestin-mediated signaling pathway. The GRK-mediated phosphorylation of the receptors plays opposite roles in conventional G protein- and β-arrestin-mediated signaling. The GRK-catalyzed phosphorylation of the receptors results in decreased G protein-mediated signaling, but it is necessary for β-arrestin-mediated signaling. Agonists that selectively activate GRK/β-arrestin-dependent signaling without affecting G protein signaling are known as β-arrestin-biased agonists. Biased agonists are expected to have potential therapeutic benefits for various diseases due to their selective activation of favorable physiological responses or avoidance of the side effects of drugs. Furthermore, GRKs are recognized as signaling mediators that are independent of either G protein- or β-arrestin-mediated pathways. GRKs can phosphorylate non-GPCR substrates, and this is found to be involved in various physiological responses, such as cell motility, development, and inflammation. In addition to these effects, our group revealed that GRK6 expressed in macrophages mediates the removal of apoptotic cells (engulfment) in a kinase activity-dependent manner. These studies revealed that GRKs block excess stimulus and also induce cellular responses. Here, we summarized the involvement of GRKs in β-arrestin-mediated and G protein-independent signaling pathways.

【 授权许可】

   
2014 Watari et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, Lefkowitz RJ: Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). Proc Natl Acad Sci U S A 1987, 84:8879-8882.
• [2]Bouvier M, Hausdorff WP, De Blasi A, O’Dowd BF, Kobilka BK, Caron MG, Lefkowitz RJ: Removal of phosphorylation sites from the beta 2-adrenergic receptor delays onset of agonist-promoted desensitization. Nature 1988, 333:370-373.
• [3]Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ: Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990, 248:1547-1550.
• [4]Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Menard L, Caron MG: Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996, 271:363-366.
• [5]Tsuga H, Kameyama K, Haga T, Kurose H, Nagao T: Sequestration of muscarinic acetylcholine receptor m2 subtypes. Facilitation by G protein-coupled receptor kinase (GRK2) and attenuation by a dominant-negative mutant of GRK2. J Biol Chem 1994, 269:32522-32527.
• [6]Ferguson SS, Menard L, Barak LS, Koch WJ, Colapietro AM, Caron MG: Role of phosphorylation in agonist-promoted beta 2-adrenergic receptor sequestration. Rescue of a sequestration-defective mutant receptor by beta ARK1. J Biol Chem 1995, 270:24782-24789.
• [7]Reiter E, Lefkowitz RJ: GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 2006, 17:159-165.
• [8]Ferguson SS: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001, 53:1-24.
• [9]Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ: Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998, 95:7000-7005.
• [10]Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA: Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 2005, 111:591-597.
• [11]Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ: Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007, 13:315-323.
• [12]Barak LS, Oakley RH, Laporte SA, Caron MG: Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 2001, 98:93-98.
• [13]Wang WC, Mihlbachler KA, Brunnett AC, Liggett SB: Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway beta2-adrenergic receptor physiologic signaling. Proc Natl Acad Sci U S A 2009, 106:15007-15012.
• [14]Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres GE, Kim KM, Lefkowitz RJ, Caron MG, Premont RT: Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 2003, 38:291-303.
• [15]Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O, Nicolas JF, Latger-Cannard V, Bensoussan D, Bordigoni P, Baleux F, Le Deist F, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F: WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005, 105:2449-2457.
• [16]Pitcher JA, Freedman NJ, Lefkowitz RJ: G protein-coupled receptor kinases. Annu Rev Biochem 1998, 67:653-692.
• [17]Penela P, Ribas C, Mayor F: Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 2003, 15:973-981.
• [18]Willets JM, Challiss RA, Nahorski SR: Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci 2003, 24:626-633.
• [19]Hisatomi O, Matsuda S, Satoh T, Kotaka S, Imanishi Y, Tokunaga F: A novel subtype of G-protein-coupled receptor kinase, GRK7, in teleost cone photoreceptors. FEBS Lett 1998, 424:159-164.
• [20]Weiss ER, Raman D, Shirakawa S, Ducceschi MH, Bertram PT, Wong F, Kraft TW, Osawa S: The cloning of GRK7, a candidate cone opsin kinase, from cone- and rod-dominant mammalian retinas. Mol Vis 1998, 4:27.
• [21]Weller M, Virmaux N, Mandel P: Light-stimulated phosphorylation of rhodopsin in the retina: the presence of a protein kinase that is specific for photobleached rhodopsin. Proc Natl Acad Sci U S A 1975, 72:381-385.
• [22]Premont RT, Macrae AD, Stoffel RH, Chung N, Pitcher JA, Ambrose C, Inglese J, MacDonald ME, Lefkowitz RJ: Characterization of the G protein-coupled receptor kinase GRK4. Identification of four splice variants. J Biol Chem 1996, 271:6403-6410.
• [23]Benovic JL, DeBlasi A, Stone WC, Caron MG, Lefkowitz RJ: Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science 1989, 246:235-240.
• [24]Benovic JL, Onorato JJ, Arriza JL, Stone WC, Lohse M, Jenkins NA, Gilbert DJ, Copeland NG, Caron MG, Lefkowitz RJ: Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family. J Biol Chem 1991, 266:14939-14946.
• [25]Kunapuli P, Benovic JL: Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc Natl Acad Sci U S A 1993, 90:5588-5592.
• [26]Benovic JL, Gomez J: Molecular cloning and expression of GRK6. A new member of the G protein-coupled receptor kinase family. J Biol Chem 1993, 268:19521-19527.
• [27]Carman CV, Parent JL, Day PW, Pronin AN, Sternweis PM, Wedegaertner PB, Gilman AG, Benovic JL, Kozasa T: Selective regulation of Galpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 1999, 274:34483-34492.
• [28]Sallese M, Mariggio S, D’Urbano E, Iacovelli L, De Blasi A: Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated galphaq. Mol Pharmacol 2000, 57:826-831.
• [29]Dhami GK, Anborgh PH, Dale LB, Sterne-Marr R, Ferguson SS: Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. J Biol Chem 2002, 277:25266-25272.
• [30]Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV: G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 2012, 133:40-69.
• [31]Eichmann T, Lorenz K, Hoffmann M, Brockmann J, Krasel C, Lohse MJ, Quitterer U: The amino-terminal domain of G-protein-coupled receptor kinase 2 is a regulatory Gbeta gamma binding site. J Biol Chem 2003, 278:8052-8057.
• [32]Premont RT, Macrae AD, Aparicio SA, Kendall HE, Welch JE, Lefkowitz RJ: The GRK4 subfamily of G protein-coupled receptor kinases. Alternative splicing, gene organization, and sequence conservation. J Biol Chem 1999, 274:29381-29389.
• [33]Inglese J, Koch WJ, Caron MG, Lefkowitz RJ: Isoprenylation in regulation of signal transduction by G-protein-coupled receptor kinases. Nature 1992, 359:147-150.
• [34]Pitcher JA, Inglese J, Higgins JB, Arriza JL, Casey PJ, Kim C, Benovic JL, Kwatra MM, Caron MG, Lefkowitz RJ: Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors. Science 1992, 257:1264-1267.
• [35]Daaka Y, Pitcher JA, Richardson M, Stoffel RH, Robishaw JD, Lefkowitz RJ: Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases. Proc Natl Acad Sci U S A 1997, 94:2180-2185.
• [36]Pitcher JA, Touhara K, Payne ES, Lefkowitz RJ: Pleckstrin homology domain-mediated membrane association and activation of the beta-adrenergic receptor kinase requires coordinate interaction with G beta gamma subunits and lipid. J Biol Chem 1995, 270:11707-11710.
• [37]Stoffel RH, Randall RR, Premont RT, Lefkowitz RJ, Inglese J: Palmitoylation of G protein-coupled receptor kinase, GRK6. Lipid modification diversity in the GRK family. J Biol Chem 1994, 269:27791-27794.
• [38]Thiyagarajan MM, Stracquatanio RP, Pronin AN, Evanko DS, Benovic JL, Wedegaertner PB: A predicted amphipathic helix mediates plasma membrane localization of GRK5. J Biol Chem 2004, 279:17989-17995.
• [39]Jiang X, Benovic JL, Wedegaertner PB: Plasma membrane and nuclear localization of G protein coupled receptor kinase 6A. Mol Biol Cell 2007, 18:2960-2969.
• [40]Johnson LR, Robinson JD, Lester KN, Pitcher JA: Distinct structural features of G protein-coupled receptor kinase 5 (GRK5) regulate its nuclear localization and DNA-binding ability. PloS One 2013, 8:e62508.
• [41]Johnson LR, Scott MG, Pitcher JA: G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol Cell Biol 2004, 24:10169-10179.
• [42]Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, Brunskill EW, Koch WJ, Schwartz RJ, Dorn GW 2nd: Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res 2006, 99:996-1003.
• [43]Nakaya M, Tajima M, Kosako H, Nakaya T, Hashimoto A, Watari K, Nishihara H, Ohba M, Komiya S, Tani N, Nishida M, Taniguchi H, Sato Y, Matsumoto M, Tsuda M, Kuroda M, Inoue K, Kurose H: GRK6 deficiency in mice causes autoimmune disease due to impaired apoptotic cell clearance. Nat Commun 2013, 4:1532.
• [44]Lefkowitz RJ, Shenoy SK: Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
• [45]Ibrahim IAAEH, Kurose H: β-arrestin-mediated signaling improves the efficacy of therapeutics. J Pharmacol Sci 2012, 118:408-412.
• [46]Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, Lefkowitz RJ: Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A 2005, 102:1442-1447.
• [47]Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ: Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A 2005, 102:1448-1453.
• [48]Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O, Lefkowitz RJ: Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem 2006, 281:1261-1273.
• [49]DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK: β-arrestins and cell signaling. Annu Rev Physiol 2007, 69:483-510.
• [50]Luttrell LM, Gesty-Palmer D: Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 2010, 62:305-330.
• [51]Schmid CL, Bohn LM: Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 2009, 121:285-293.
• [52]Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, Chen JR, Muehlbauer MJ, Whalen EJ, Lefkowitz RJ: Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Investig 2009, 119:1312-1321.
• [53]Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, Luttrell LM: A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 2009, 1:1ra1.
• [54]Kim KS, Abraham D, Williams B, Violin JD, Mao L, Rockman HA: Beta-arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 2012, 303:H1001-H1010.
• [55]Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA: Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Investig 2007, 117:2445-2458.
• [56]Rajagopal S, Rajagopal K, Lefkowitz RJ: Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386.
• [57]Kenakin T, Miller LJ: Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010, 62:265-304.
• [58]Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, Benovic JL, Carlson KE, Hunt SW 3rd, Bouvier M: Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A 2013, 110:E5088-E5097.
• [59]Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW: Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010, 335:572-579.
• [60]Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, Rockman HA: Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 2008, 105:14555-14560.
• [61]Violin JD, Lefkowitz RJ: Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422.
• [62]Whalen EJ, Rajagopal S, Lefkowitz RJ: Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 2011, 17:126-139.
• [63]Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K: Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science 2012, 335:1106-1110.
• [64]Sauliere A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altie MF, Seguelas MH, Pathak A, Hansen JL, Senard JM, Gales C: Deciphering biased-agonism complexity reveals a new active AT(1) receptor entity. Nat Chem Biol 2012, 8:622-630.
• [65]Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ: Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A 2009, 106:9649-9654.
• [66]Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL: Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010, 285:7805-7817.
• [67]Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, Bottrill A, Mistry S, Tobin AB: Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J Biol Chem 2011, 286:11506-11518.
• [68]Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, Strachan RT, Huang TY, Bressler EA, Hara MR, Shenoy SK, Gygi SP, Lefkowitz RJ: Distinct phosphorylation sites on the 2-adrenergic receptor establish a barcode that encodes differential functions of -arrestin. Sci Signal 2011, 4:ra51-ra51.
• [69]Liggett SB: Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci Signal 2011, 4:pe36.
• [70]DeWire SM, Violin JD: Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 2011, 109:205-216.
• [71]Tilley DG: G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 2011, 109:217-230.
• [72]Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
• [73]Nakaya M, Chikura S, Watari K, Mizuno N, Mochinaga K, Mangmool S, Koyanagi S, Ohdo S, Sato Y, Ide T, Nishida M, Kurose H: Induction of cardiac fibrosis by beta-blocker in G protein-independent and G protein-coupled receptor kinase 5/beta-arrestin2-dependent Signaling pathways. J Biol Chem 2012, 287:35669-35677.
• [74]Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J: Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005, 115:3045-3056.
• [75]Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, Coffman TM, Rockman HA, Lefkowitz RJ: Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A 2006, 103:16284-16289.
• [76]Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ: {beta}-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 2009, 284:8855-8865.
• [77]Kurose H: Atypical actions of G protein-coupled receptor kinases. Biomolecules and Therapeutics 2011, 19:390-397.
• [78]Freedman NJ, Kim LK, Murray JP, Exum ST, Brian L, Wu JH, Peppel K: Phosphorylation of the platelet-derived growth factor receptor-beta and epidermal growth factor receptor by G protein-coupled receptor kinase-2. Mechanisms for selectivity of desensitization. J Biol Chem 2002, 277:48261-48269.
• [79]Hildreth KL, Wu JH, Barak LS, Exum ST, Kim LK, Peppel K, Freedman NJ: Phosphorylation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-2 reduces receptor signaling and interaction with the Na(+)/H(+) exchanger regulatory factor. J Biol Chem 2004, 279:41775-41782.
• [80]Barthet G, Carrat G, Cassier E, Barker B, Gaven F, Pillot M, Framery B, Pellissier LP, Augier J, Kang DS, Claeysen S, Reiter E, Baneres JL, Benovic JL, Marin P, Bockaert J, Dumuis A: Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling. EMBO J 2009, 28:2706-2718.
• [81]Lafarga V, Aymerich I, Tapia O, Mayor F Jr, Penela P: A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J 2012, 31:856-869.
• [82]Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC: A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005, 11:952-958.
• [83]Martini JS, Raake P, Vinge LE, DeGeorge BR Jr, Chuprun JK, Harris DM, Gao E, Eckhart AD, Pitcher JA, Koch WJ: Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 2008, 105:12457-12462.
• [84]Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC, Benovic JL: Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J Biol Chem 2006, 281:34159-34170.
• [85]Patial S, Luo J, Porter KJ, Benovic JL, Parameswaran N: G-protein-coupled-receptor kinases mediate TNFalpha-induced NFkappaB signalling via direct interaction with and phosphorylation of IkappaBalpha. Biochem J 2010, 425:169-178.
• [86]Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, Galasso G, Astone D, Piscione F, Pastore L, Trimarco B, Iaccarino G: The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci U S A 2008, 105:17818-17823.
• [87]Ho J, Cocolakis E, Dumas VM, Posner BI, Laporte SA, Lebrun JJ: The G protein-coupled receptor kinase-2 is a TGFbeta-inducible antagonist of TGFbeta signal transduction. EMBO J 2005, 24:3247-3258.
• [88]Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, Mayor F Jr, Murga C: Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr Biol 2006, 16:2042-2047.
• [89]Wang L, Gesty-Palmer D, Fields TA, Spurney RF: Inhibition of WNT signaling by G protein-coupled receptor (GPCR) kinase 2 (GRK2). Mol Endocrinol 2009, 23:1455-1465.
• [90]Penela P, Ribas C, Aymerich I, Eijkelkamp N, Barreiro O, Heijnen CJ, Kavelaars A, Sanchez-Madrid F, Mayor F Jr: G protein-coupled receptor kinase 2 positively regulates epithelial cell migration. EMBO J 2008, 27:1206-1218.
• [91]Penela P, Rivas V, Salcedo A, Mayor F Jr: G protein-coupled receptor kinase 2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci USA 2010, 107:1118-1123.
• [92]Michal AM, So CH, Beeharry N, Shankar H, Mashayekhi R, Yen TJ, Benovic JL: G Protein-coupled receptor kinase 5 is localized to centrosomes and regulates cell cycle progression. J Biol Chem 2012, 287:6928-6940.
• [93]Jimenez-Sainz MC, Murga C, Kavelaars A, Jurado-Pueyo M, Krakstad BF, Heijnen CJ, Mayor F Jr, Aragay AM: G protein-coupled receptor kinase 2 negatively regulates chemokine signaling at a level downstream from G protein subunits. Mol Biol Cell 2006, 17:25-31.
• [94]Usui I, Imamura T, Babendure JL, Satoh H, Lu JC, Hupfeld CJ, Olefsky JM: G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol 2005, 19:2760-2768.
• [95]Shiina T, Arai K, Tanabe S, Yoshida N, Haga T, Nagao T, Kurose H: Clathrin box in G protein-coupled receptor kinase 2. J Biol Chem 2001, 276:33019-33026.
• [96]Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA: Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 2001, 276:18953-18959.
• [97]Premont RT, Claing A, Vitale N, Freeman JL, Pitcher JA, Patton WA, Moss J, Vaughan M, Lefkowitz RJ: Beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. Proc Natl Acad Sci U S A 1998, 95:14082-14087.
• [98]Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, Dorn GW 2nd, Trimarco B, Feliciello A, Iaccarino G: Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. Cell Signal 2012, 24:468-475.
• [99]Luo J, Benovic JL: G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. J Biol Chem 2003, 278:50908-50914.
• [100]Chen M, Sato PY, Chuprun JK, Peroutka RJ, Otis NJ, Ibetti J, Pan S, Sheu SS, Gao E, Koch WJ: Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ Res 2013, 112:1121-1134.
• [101]Obrenovich ME, Palacios HH, Gasimov E, Leszek J, Aliev G: The GRK2 overexpression is a primary hallmark of mitochondrial lesions during early alzheimer disease. Cardiovascular Psychiatry and Neurology 2009, 2009:327360.
• [102]Carman CV, Som T, Kim CM, Benovic JL: Binding and phosphorylation of tubulin by G protein-coupled receptor Kinases. J Biol Chem 1998, 273:20308-20316.
• [103]Pitcher JA, Hall RA, Daaka Y, Zhang J, Ferguson SS, Hester S, Miller S, Caron MG, Lefkowitz RJ, Barak LS: The G protein-coupled receptor Kinase 2 is a microtubule-associated protein Kinase that phosphorylates tubulin. J Biol Chem 1998, 273:12316-12324.
• [104]Haga K, Ogawa H, Haga T, Murofushi H: GTP-binding-protein-coupled receptor kinase 2 (GRK2) binds and phosphorylates tubulin. Eur J Biochem 1998, 255:363-368.
• [105]Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS: Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 2007, 129:511-522.
• [106]Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L: G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J Biol Chem 2010, 285:12823-12830.
• [107]Rivas V, Carmona R, Munoz-Chapuli R, Mendiola M, Nogues L, Reglero C, Miguel-Martin M, Garcia-Escudero R, Dorn GW 2nd, Hardisson D, Mayor F Jr, Penela P: Developmental and tumoral vascularization is regulated by G protein-coupled receptor kinase 2. J Clin Invest 2013, 123:4714-4730.
• [108]Burkhalter MD, Fralish GB, Premont RT, Caron MG, Philipp M: Grk5l controls heart development by limiting mTOR signaling during symmetry breaking. Cell Rep 2013, 4:625-632.
• [109]Shukla AK, Xiao K, Lefkowitz RJ: Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 2011, 36:457-469.
• [110]Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ: Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
• [111]Bychkov ER, Ahmed MR, Gurevich VV, Benovic JL, Gurevich EV: Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. Neurobiol Dis 2011, 44:248-258.
• [112]Grange-Midroit M: Regulation of GRK 2 and 6, β-arrestin-2 and associated proteins in the prefrontal cortex of drug-free and antidepressant drug-treated subjects with major depression. Mol Brain Res 2003, 111:31-41.
• [113]White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ: Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A 2000, 97:5428-5433.
• [114]Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD, Lefkowitz RJ, Koch WJ: In vivo ventricular gene delivery of a -adrenergic receptor Kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
• [115]Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE, Koch WJ: Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009, 119:89-98.
• [116]Rengo G, Lymperopoulos A, Leosco D, Koch WJ: GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011, 50:785-792.
• [117]Carotenuto A, Cipolletta E, Gomez-Monterrey I, Sala M, Vernieri E, Limatola A, Bertamino A, Musella S, Sorriento D, Grieco P, Trimarco B, Novellino E, Iaccarino G, Campiglia P: Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors. Eur J Med Chem 2013, 69:384-392.
• [118]Thal DM, Homan KT, Chen J, Wu EK, Hinkle PM, Huang ZM, Chuprun JK, Song J, Gao E, Cheung JY, Sklar LA, Koch WJ, Tesmer JJ: Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 2012, 7:1830-1839.